Actuate Therapeutics

Contributing Author

Recent Articles by Actuate Therapeutics

Jun-24	Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial ACTU GlobeNewswire
Jun-20	Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO ACTU GlobeNewswire
Jun-16	Actuate Therapeutics Announces Inclusion in the Russell 3000 and Russell 2000 Indexes ACTU GlobeNewswire
Jun-02	Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer ACTU GlobeNewswire
May-31	Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer ACTU GlobeNewswire
May-22	Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer ACTU GlobeNewswire
May-07	Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting ACTU GlobeNewswire
May-06	Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer ACTU GlobeNewswire